Nelfinavir Mesylate
FDA-approved product (powder, oral), marketed as Viracept.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- HIV-1 infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE04
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nelfinavir Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
NCT00002378
Registered record
- Registry ID
- NCT00002378
- Conditions
- HIV Infections
- Interventions
- Ritonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate; Lamivudine; Stavudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 825
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionRitonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate +3 morePhasePhase 3Registry statusCompletedThe Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
NCT00002381
Registered record
- Registry ID
- NCT00002381
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate; Nevirapine; Stavudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionNelfinavir mesylate; Nevirapine; StavudinePhasePhase 1Registry statusCompletedThe Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
NCT00005118
Registered record
- Registry ID
- NCT00005118
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir sulfate; RitonavirPhasePhase 2Registry statusUnknownRitonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
NCT00006591
Registered record
- Registry ID
- NCT00006591
- Conditions
- HIV Infections
- Interventions
- Ritonavir; Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionRitonavir; AmprenavirPhaseNot applicableRegistry statusUnknownHormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
NCT00044837
Registered record
- Registry ID
- NCT00044837
- Conditions
- HIV Infections
- Interventions
- Medroxyprogesterone acetate; Estradiol
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionMedroxyprogesterone acetate; EstradiolPhasePhase 1Registry statusTerminated